Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
- PMID: 26001971
- DOI: 10.1016/j.canlet.2015.05.013
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
Abstract
Chromosomal rearrangements of the NTRK1 gene, which encodes the high affinity nerve growth factor receptor (tropomyosin related kinase, TRKA), have been observed in several epithelial cancers, such as colon cancer, papillary thyroid carcinoma or non small cell lung cancer. The various NTRK1 fusions described so far lead to constitutive activation of TRKA kinase activity and are oncogenic. We further investigated here the existence and the frequency of NTRK1 gene rearrangements in colorectal cancer. Using immunohistochemistry and quantitative reverse transcriptase PCR, we analyzed a series of human colorectal cancers. We identified two TRKA positive cases over 408, with NTRK1 chromosomal rearrangements. One of these rearrangements is a TPM3-NTRK1 fusion already observed in colon cancer, while the second one is a TPR-NTRK1 fusion never described in this type of cancer. These findings further confirm that translocations in the NTRK1 gene are recurring events in colorectal cancer, although occurring at a low frequency (around 0.5%).
Keywords: Colon cancer; Gene rearrangement; NTRK1; TRKA.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.Genomics. 1995 Jul 1;28(1):15-24. doi: 10.1006/geno.1995.1100. Genomics. 1995. PMID: 7590742
-
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.J Natl Cancer Inst. 2015 Nov 12;108(1):djv306. doi: 10.1093/jnci/djv306. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26563355 Free PMC article.
-
Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.Mutat Res. 2006 Jul 25;599(1-2):26-35. doi: 10.1016/j.mrfmmm.2005.12.013. Epub 2006 Feb 17. Mutat Res. 2006. PMID: 16483615
-
Oncogenic rearrangements of the NTRK1/NGF receptor.Cancer Lett. 2006 Jan 28;232(1):90-8. doi: 10.1016/j.canlet.2005.07.043. Epub 2005 Oct 20. Cancer Lett. 2006. PMID: 16242838 Review.
-
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.Mol Cell Endocrinol. 2010 May 28;321(1):44-9. doi: 10.1016/j.mce.2009.10.009. Epub 2009 Oct 31. Mol Cell Endocrinol. 2010. PMID: 19883730 Review.
Cited by
-
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. eCollection 2016. Front Oncol. 2016. PMID: 27200298 Free PMC article. Review.
-
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.Br J Pharmacol. 2020 Jul;177(13):3060-3074. doi: 10.1111/bph.15034. Epub 2020 Apr 12. Br J Pharmacol. 2020. PMID: 32087611 Free PMC article.
-
Precision oncology in metastatic colorectal cancer - from biology to medicine.Nat Rev Clin Oncol. 2021 Aug;18(8):506-525. doi: 10.1038/s41571-021-00495-z. Epub 2021 Apr 16. Nat Rev Clin Oncol. 2021. PMID: 33864051 Review.
-
Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.Future Oncol. 2018 Apr;14(10):947-962. doi: 10.2217/fon-2017-0597. Epub 2018 Mar 15. Future Oncol. 2018. PMID: 29542354 Free PMC article. Review.
-
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.Int J Mol Sci. 2020 Jan 23;21(3):753. doi: 10.3390/ijms21030753. Int J Mol Sci. 2020. PMID: 31979374 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous